SYNACT — SynAct Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK908.29m
- SEK894.99m
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development
Brief: SynAct Pharma CEO And CSO Sell Shares
Sweden's SynAct Pharma Q2 net loss narrows on lower expenses
Brief: Synact Pharma Q2 Group Loss After Tax At SEK 22 Mln
Brief: SynAct Pharma Q2 Sales SEK 0
Development And Commercialization Partnership With Hipolabor In Brazil
Brief: Synact Pharma Receives Favorable Us Patent Decision For Immediate-Release Resomelagon Tablet Formulation
Brief: Synact Pharma Draws SEK 50 Mln Under Facility Via Convertible Loans
Brief: Synact Pharma Reports Preclinical Data
Brief: SynAct: Shareholding Board, Management Sign Lock-Up Agreements
Sweden's SynAct Pharma posts wider Q1 net loss as expenses rise
Brief: SynAct Pharma Q1 Sales SEK 0
Brief: SynAct Pharma Carries Out Directed Issue Of New Shares
Brief: Synact Pharma Appoints Ann Kristin Led As CFO Effective March 2026
Sweden's SynAct Pharma Q4 net loss widens as expenses rise
Brief: SynAct Pharma Q4 Sales SEK 0